Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stangel

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2002
Despair of repairM Stangel, H-P Hartung
Der Nervenarzt|April 27, 2002
[Intravenous immunoglobulins in multiple sclerosis. Studies and mechanisms of action--an update]M Stangel, H P Hartung
European Neurology|February 20, 1999
Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disordersM Stangel, M Müller, P Marx
Der Nervenarzt|September 28, 2018
[Neurological complications of infections with (novel) enteroviruses]N Möhn, T Skripuletz, M Stangel
Der Nervenarzt|September 15, 2005
[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ]C Trebst, H Wiendl, M Stangel
Der Nervenarzt|February 9, 2013
[Neurological complications of inflammatory bowel diseases]N Cieplik, M Stangel, O Bachmann
Cerebrovascular Diseases (Basel, Switzerland)|November 5, 1999
Presentation and prognosis of bilateral infarcts in the territory of the superior cerebellar arteryM Stangel, C Stapf, P Marx
Clinical Immunology (Orlando, Fla.)|March 19, 2011
Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of actionR Gold, R A Linker, M Stangel
Journal of Neuroimmunology|March 4, 2000
Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg")M Stangel, A Compston, N J Scolding
Archives of Neurology|June 16, 1999
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseasesM Stangel, K V Toyka, R Gold
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2002
Despair of repairM Stangel, H-P Hartung
Der Nervenarzt|April 27, 2002
[Intravenous immunoglobulins in multiple sclerosis. Studies and mechanisms of action--an update]M Stangel, H P Hartung
European Neurology|February 20, 1999
Adverse events during treatment with high-dose intravenous immunoglobulins for neurological disordersM Stangel, M Müller, P Marx
Der Nervenarzt|September 28, 2018
[Neurological complications of infections with (novel) enteroviruses]N Möhn, T Skripuletz, M Stangel
Der Nervenarzt|September 15, 2005
[Concepts of lesion development in multiple sclerosis. Current approaches and clinical-therapeutic implications ]C Trebst, H Wiendl, M Stangel
Der Nervenarzt|February 9, 2013
[Neurological complications of inflammatory bowel diseases]N Cieplik, M Stangel, O Bachmann
Cerebrovascular Diseases (Basel, Switzerland)|November 5, 1999
Presentation and prognosis of bilateral infarcts in the territory of the superior cerebellar arteryM Stangel, C Stapf, P Marx
Clinical Immunology (Orlando, Fla.)|March 19, 2011
Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of actionR Gold, R A Linker, M Stangel
Journal of Neuroimmunology|March 4, 2000
Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins ("IVIg")M Stangel, A Compston, N J Scolding
Archives of Neurology|June 16, 1999
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseasesM Stangel, K V Toyka, R Gold
Pageof 7